FindTrial
Sign In

A Phase 2 study of S-237648 in Japanese obese patients with impaired glucose tolerance/type 2 diabetes mellitus and hyperlipidemia

A Phase 2 study of S-237648 in Japanese obese patients with impaired glucose tolerance/type 2 diabetes mellitus and hyperlipidemia

Status
Unknown
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222949
Enrollment
Unknown
Registered
2015-08-31
Start date
2015-08-31
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Interventions

investigational material(s) Generic name etc : S-237648 INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration for I

Sponsors

Shionogi & Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: [Main inclusion criteria] 1.With BMI >=25.0 2.With visceral fat area >=100 cm2 3.Patients who meets following criteria A)Previously diagnosed with glucose intolerance or type 2 diabetes [HbA1c >=6.5% to =150 mg/dL and/or HDL-C =140 mg/dL

Exclusion criteria

Exclusion criteria: [Main exclusion criteria] 1.Patients with symptomatic obesity 2.Patients with serious hepatic, renal, cardiovascular, respiratory, or hematological disorders

Design outcomes

Primary

MeasureTime frame
Change in body weight—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026